Venture • Life Science

HBM Partners Invests In NiKang Therapeutics

On September 14, 2020, private equity firm HBM Partners invested in life science company NiKang Therapeutics

Investment Context

This is HBM Partners’ 33rd transaction in the Life Science sector.
This is HBM Partners’ 27th transaction in the United States.
This is HBM Partners’ 1st transaction in Delaware.

Explore All 557 Venture Life Science Deals - Search the Database Free

Investment Summary
Date	September 14, 2020
Target	NiKang Therapeutics
Sector	Life Science
Investor(s)	HBM Partners
Deal Type	Venture

Target Company

NiKang Therapeutics

Wilmington, Delaware, United States

NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. NiKang’s discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies. NiKang Therapeutics was founded in 2017 and is based in Wilmington, Delaware.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Investor Overview 1

Investor

HBM Partners

Investor Investor

Category	Private Equity Firm
Founded	2001
PE ASSETS	2.1B USD
Size	Large
Type	Sector Focused

DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

Deal Context for Investor	#
Overall	40 of 66
Sector: Life Science	33 of 56
Type: Venture	31 of 52
State: Delaware	1 of 1
Country: United States	27 of 44
Year: 2020	10 of 17

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2020-08-24	Connect Biopharma San Diego, California, United States Connect Biopharma is a global biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. Connect Biopharma was founded in 2012 and is based in San Diego, California.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2020-08-24

Connect Biopharma

San Diego, California, United States

Connect Biopharma is a global biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. Connect Biopharma was founded in 2012 and is based in San Diego, California.

Buy

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2020-09-16	Polyneuron Basel, Switzerland Polyneuron has a unique approach in using antigen-specific polymers to target and eliminate the pathological antibodies causing serious autoimmune diseases with a high unmet medical need. Polyneuron was founded in 2014 and is based in Basel, Switzerland.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2020-09-16

Polyneuron

Basel, Switzerland

Polyneuron has a unique approach in using antigen-specific polymers to target and eliminate the pathological antibodies causing serious autoimmune diseases with a high unmet medical need. Polyneuron was founded in 2014 and is based in Basel, Switzerland.

Buy

Explore Related M&A Activity

Life Science M&A - Venture M&A Deals - Delaware M&A - United States M&A - 2020 M&A